GlassScriptPhysician profile
Wayne Joseph Overman
NPI 1306258777
$1,391.77
in general payments reported to CMS, 2019-2025
15 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $119 · 2021: $230 · 2022: $107 · 2023: $214 · 2024: $87.76 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $375.91 | 2020-2025 | |
| Allergan, INC. | $165.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $151.63 | 2022-2025 | |
| Galderma Laboratories, L.P. | $133.32 | 2019 | |
| Misonix INC | $114.92 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $108.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $100.77 | 2019-2025 | Libtayo |
| Sun Pharmaceutical Industries INC. | $56.02 | 2020-2023 | Winlevi |
| Lilly USA, LLC | $49.15 | 2020-2021 | |
| Dermira, INC. | $31.84 | 2019-2020 | |
| Organogenesis INC. | $29.33 | 2025 | Novachor |
| Genzyme Corporation | $23.64 | 2021 | |
| Biowound Solutions, INC. | $21.91 | 2024 | Bio-Connekt |
| Incyte Corporation | $18.64 | 2022 | |
| Organon LLC | $10.18 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Overman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.